Navigating the complexities of epigenetic dysregulation in breast cancer and its implication in therapeutic interventions: a comprehensive overview
Authors:
- 23 October 2025
- journal article
- review article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (1) , 171-186
Abstract
Breast cancer represents a multifaceted and heterogeneous condition characterized by both genetic and epigenetic alterations. Among these, epigenetic modifications—such as DNA methylation, histone modifications, chromatin remodeling, and noncoding RNAs—play pivotal roles in tumor initiation, progression, therapeutic resistance, and immune evasion. These alterations contribute to dysregulation of estrogen signalling, endocrine therapy resistance, and metabolic rewiring, posing challenges for conventional treatment strategies. Notably, our previous findings reveal that 27-hydroxycholesterol, an endogenous selective estrogen modulator, can induce epigenetic changes in (ER)-positive breast cancer cells. This review provides a comprehensive overview of the landscape of epigenetic dysregulation in breast cancer, emphasizing its impact on disease progression and therapeutic resistance. It details the intricate interplay between epigenetic players and the tumor immune microenvironment, which plays a crucial role in shaping treatment responses. In addition, the review highlights the on-going clinical trials and suggests addressing the gaps present in dissecting pathways of epigenetic reprogramming in breast cancer evolution and therapy outcomes. Unraveling these mechanisms reinstates opportunities for potential therapies targeting epigenetic pathways along with the conventional medicine, which is required in transformation of clinical management of breast cancer and potential enhancement of the patient’s lifespan.Keywords
Funding Information
- DBT BioCARe grant (BT/50706/BIC/101/1288/2023))
This publication has 102 references indexed in Scilit:
- DNMT1 prolonged absence is a tunable cellular stress that triggers cell proliferation arrest to protect from major DNA methylation lossCellular and Molecular Life Sciences, 2024
- A comprehensive study on epigenetic signatures to monitor disease progression and the response to therapy in breast cancerBiomedical Analysis, 2024
- Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategiesBiomedicine & Pharmacotherapy, 2024
- HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancerCell Chemical Biology, 2023
- Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseasesGenes & Diseases, 2023
- SWI/SNF Chromatin Remodelers: Structural, Functional and Mechanistic ImplicationsCell Biochemistry and Biophysics, 2023
- Recent advances in nanoparticle-based photothermal therapy for breast cancerJournal of Controlled Release, 2022
- Understanding the interplay between CpG island-associated gene promoters and H3K4 methylationBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2020
- Overcoming Endocrine Resistance in Breast CancerCancer Cell, 2020
- Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 AcetylationCell Reports, 2019